Fluoride salts for vertebral osteoporosis: the benefit-to-risk ratio depends on the cumulative dose reaching bone.
Meunier
P J
PJ
INSERM Unit 234, Edouard Herriot Hospital, Lyon, France.
Boivin
G
G
D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004064:Digestive System / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005459:Fluorides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007596:Joints / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D010146:Pain / Q000139:chemically induced; D011446:Prospective Studies; D011884:Radius / Q000187:drug effects; D012492:Salts; D013122:Spinal Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
D012492:Salts; D005459:Fluorides